A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)
Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study will find the dose limiting toxicities (DLTs), maximum tolerated dose (MTD), and
recommended Phase 2 dose (RPTD) of MK4827 when administered in combination with standard
doses of carboplatin, or carboplatin/paclitaxel, or carboplatin/liposomal doxorubicin in the
treatment of advanced solid cancers in adults.